Conversely, the effect of the VEGF-C/VEGF-D trap is currently being evaluated in a phase 3 clinical trial on wet-type age-associated macular degeneration and in a phase 2 clinical trial on diabetic macular edema (ClinicalTrials.gov identifier NCT02543229). The gene discussed is VEGFD; the disease is diabetic macular edema.